Anika Therapeutics, Inc. (NASDAQ:ANIK) today announced the
appointment of Joseph Darling as Chief Executive Officer,
succeeding Dr. Charles Sherwood, who will retire as Chief Executive
Officer and a director of Anika on March 9, 2018, after almost 20
years of service. Mr. Darling, who succeeded Dr. Sherwood as
Anika’s President in July 2017, will serve as Chief Executive
Officer, President and a director of Anika.
“First, I would like to thank Chuck Sherwood for his close to
two decades of commitment to Anika and for establishing Anika as a
global innovator in joint health and tissue repair,” said Joseph
Bower, Chairman of Anika’s Board of Directors. “Chuck Sherwood
built Anika as we know it. As CEO for 15 years, he has delivered
outstanding product innovation and development and operational,
commercial, and financial achievements. Chuck has worked tirelessly
and successfully to position the Company well as it enters its next
phase of growth. His contributions to Anika and its constituents
are too numerous to recount, and he leaves a clear and positive
legacy. We wish him all the best in his retirement.”
“Among the most important responsibilities of a CEO is preparing
for succession. That process began almost two years ago with
discussions between Chuck Sherwood and the Board followed by an
extensive search. The handing of the CEO mantle to Joe Darling
reflects Anika’s evolution to a new and exciting phase of direct
commercial activity, driven by a series of novel technologies that
can both disrupt and expand the growing need for non-opioid joint
pain solutions and more effective orthopedic regenerative healing
technologies,” continued Dr. Bower.
President and newly named CEO Joseph Darling said, “Anika is at
the cusp of transformational growth. It is an honor and a great
opportunity to lead such a talented group of people as we seek to
invest in and deliver a series of novel and impactful new
treatments to the global orthopedic community over the coming
years. Our mandate going forward is clear - we plan to make Anika’s
HA-based solutions a standard of care for a number of the most
common conditions associated with aging and injury. By achieving
that goal through the U.S. launch of CINGAL and other innovative
therapies, along with driving financial value associated with a
direct commercial effort, we believe we will position the Company
to accelerate revenue and earnings growth over the next several
years and beyond.”
Mr. Darling joined Anika as President in July 2017, bringing
more than 20 years of extensive experience in executive management
and leadership from publicly-traded, commercial-stage companies,
including Abbott Laboratories, Baxter Healthcare, Smith &
Nephew, CONMED, and Wyeth-Ayerst. Most recently, Mr. Darling held
executive leadership positions with two small privately held
orthopedic companies. Prior to these roles, Mr. Darling held senior
level executive positions at CONMED Corporation, a global,
publicly-held, diversified medical device company, as Global
President of its wholly-owned subsidiary, Linvatec Corporation, and
as Executive Vice President of Global Corporate Commercial
Operations. At CONMED, Mr. Darling led five global business units
with approximately $760 million in annual revenues and re-energized
the organizational efforts in sales, marketing, R&D, and
business development activities that allowed the company to expand
its portfolio of product offerings to its customers. Mr. Darling
oversaw the launch and commercialization of many key new products
while at Linvatec including several new sports medicine
technologies in the shoulder (Shoulder Restoration System, Y-Knot
Shoulder Anchor line), along with new products in the knee and hip
joints. Before joining CONMED, Mr. Darling was Senior Vice
President and General Manager for the sports medicine and biologics
business at Smith & Nephew, where he played an important role
in defining a global strategy that propelled the company to a
leadership position in the sports medicine field. While at Smith
& Nephew, Mr. Darling and his team were pioneers in developing
the Hip Arthroscopy space from a commercial perspective. Mr.
Darling launched his career at Abbott Laboratories where he was
involved in the commercialization efforts of many pharmaceutical
products in the neuroscience, antimicrobial, cardiovascular, and
HIV treatment space. While at Abbott Laboratories, he held
management positions in sales and marketing before joining
Wyeth-Ayerst Pharmaceuticals in roles of marketing for the pain and
inflammation and women’s healthcare franchises. He later joined
Baxter Healthcare as a Vice President of marketing and health
systems. Mr. Darling holds a Bachelor of Arts in Political Science
from Syracuse University.
About Anika Therapeutics, Inc.
Anika Therapeutics, Inc. (NASDAQ:ANIK) is
a global, integrated orthopedic medicines company based
in Bedford, Massachusetts. Anika is committed to improving the
lives of patients with degenerative orthopedic diseases and
traumatic conditions with clinically meaningful therapies along the
continuum of care, from palliative pain management to regenerative
tissue repair. The Company has over two decades of global expertise
developing, manufacturing, and commercializing more than 20
products based on its proprietary hyaluronic acid (HA) technology.
Anika's orthopedic medicine portfolio includes ORTHOVISC, MONOVISC,
and CINGAL, which alleviate pain and restore joint function by
replenishing depleted HA, and HYALOFAST, a solid HA-based
scaffold to aid cartilage repair and regeneration. For more
information about Anika, please visit
www.anikatherapeutics.com.
ANIKA, ANIKA THERAPEUTICS, CINGAL, HYALOFAST, MONOVISC, and
ORTHOVISC are our registered trademarks. This press release may
contain registered marks, trademarks and trade names that are the
property of other companies.
Forward-Looking Statements
The statements made in the third and fourth paragraphs of this
press release, which are not statements of historical fact, are
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. These statements include, but are not limited to,
those relating to the Company's direct commercial activity, use of
novel technologies, delivery of new orthopedic treatments, launch
of CINGAL and other therapies, and revenue and earnings growth.
These statements are based upon the current beliefs and
expectations of the Company's management and are subject to
significant risks, uncertainties and other factors. The Company's
actual results could differ materially from any anticipated future
results, performance, or achievements described in the
forward-looking statements as a result of a number of factors
including, but not limited to: (i) the Company's ability to
successfully commence and/or complete clinical trials of its
products on a timely basis or at all; (ii) the Company's ability to
obtain pre-clinical or clinical data to support domestic and
international pre-market approval applications, 510(k)
applications, or new drug applications, or to timely file and
receive FDA or other regulatory approvals or clearances of its
products; (iii) that such approvals will not be obtained in a
timely manner or without the need for additional clinical trials,
other testing or regulatory submissions, as applicable; (iv) the
Company's research and product development efforts and their
relative success, including whether we have any meaningful sales of
any new products resulting from such efforts; (v) the cost
effectiveness and efficiency of the Company's clinical studies,
manufacturing operations, and production planning; (vi) the
strength of the economies in which the Company operates or will be
operating, as well as the political stability of any of those
geographic areas; (vii) future determinations by the Company to
allocate resources to products and in directions not presently
contemplated; (viii) the Company's ability to successfully
commercialize its products, in the U.S. and abroad; (ix) the
Company's ability to provide an adequate and timely supply of its
products to its customers; and (x) the Company's ability to achieve
its growth targets. Additional factors and risks are described in
the Company's periodic reports filed with the Securities and
Exchange Commission, and they are available on the SEC's website at
www.sec.gov. Forward-looking statements are made based on
information available to the Company on the date of this press
release, and the Company assumes no obligation to update the
information contained in this press release.
For Investor Inquiries: Anika Therapeutics, Inc. Sylvia Cheung,
781-457-9000 Chief Financial Officer |
For Media Inquiries: Pure Communications Sonal Vasudev,
917-523-1418 sonal@purecommunicationsinc.com |
Anika Therapeutics (NASDAQ:ANIK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Anika Therapeutics (NASDAQ:ANIK)
Historical Stock Chart
From Apr 2023 to Apr 2024